RE:AUSTIN48First book value speaks more to equity than assets. If you sell everything and pay your debt, how much do you have left? Also, you are using Tangible book value which doesn't account for intangible assets. That could change those ratios (I don't have time right now to check through each balance sheet).
Second, if we look at quick ratios, short term assets to short term liabilities, that'll paint a bleak picture for Zenabis. From the last time I looked at each of those companies listed, they had much better cash positions. Cash is king right now. No cash = dilution at this stage.
All of that aside, please put together a real argument as to why Zenabis is worth over $400,000,000 in your mind. Why should this trade at 5.5x 2019 earnings (probably 4x 2020 earnings)?
You say obviously the best deal is Zenabis. They have debt coming due this year that they can't pay. I'm also in Delta 9 and I think that D9 has more chance to be a good long term play.
I'm invested in Zenabis, I'm not bashing, I'm calling it how it is. I imagine there will be more dilution to clear the debt coming due in a few months. That said, if we get to a total float of 600,000,000 shares outstanding, they can probably each the $0.30 point in the near future, which is a 100% gain on today's price. That's why I'm here, not to make 10x the cash, but probably 2x the cash. Let's be realistic.